Intas to Build a Large-Scale MAb Manufacturing Unit in India

January 19, 2009

Indian biotechnology company Intas Biopharmaceuticals (IBPL, Ahmedabad, Gujarat) has signed a memorandum of understanding (MoU) with the government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs).

Indian biotechnology company Intas Biopharmaceuticals (IBPL, Ahmedabad, Gujarat) has signed a memorandum of understanding (MoU) with the government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs).

The facility, dedicated for MAbs, will undertake large-scale manufacturing of the recombinant product with a capacity of 5,000 L in phases. The government of Gujarat will help the company obtain incentives under various schemes announced by the state and central government.

IBPL is already manufacturing and marketing biosimilars including GCSF, Interferon, Erythropoietin, and PEG-GCSF. The commercial production at the proposed MAbs facility is likely to commence by 2011.